INOVIO PHARMACEUTICALS, INC. (INO)

2.49 0.03 (1.22%)

As of 2025-10-16 18:48:04 EST

Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).

Traded asNasdaq: INO
ISINUS45773H4092
CIK0001055726
LEI529900B9W875XDZXTM97
EIN330969592
SectorBiotechnology
IndustryPharmaceutical Preparations
CEOJacqueline Shea, Ph.D.
Employees262
Fiscal Year End1231
Address660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
Phone8584103134
Websitehttps://www.inovio.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
INOINOVIO PHARMACEUTICALS, INC.2025-10-16 18:48:042.490.031.22
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
INO0001055726INOVIO PHARMACEUTICALS, INC.US45773H4092529900B9W875XDZXTM97330969592Nasdaq2834Pharmaceutical Preparations1231DE660 W. GERMANTOWN PIKEPLYMOUTH MEETINGPA19462UNITED STATESUS8584103134660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462INOVIO BIOMEDICAL CORPBiotechnology1999Jacqueline Shea, Ph.D.262https://www.inovio.com208,000,00036,718,52753,142,661Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).2025-10-10 22:45:40
This is a preview of the latest data. Subscribe to access the full data.
INO Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
INO Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024208,000,00088,300,00073.767836,667,22113,296,85656.8962
2023119,700,000-305,800,000-71.868423,370,365-236,761,621-91.016
2022425,500,000-1,474,500,000-77.6053260,131,98642,728,69919.6541
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Peter D. KiesChief Financial Officer2024506,8060131,957—15,204940,072
Jacqueline E. SheaChief Executive Officer, President2024728,0000490,819—15,1692,050,669
Michael Sumner, M.D.Chief Medical Officer2024532,00047,133139,596—15,2501,037,406
Peter D. KiesChief Financial Officer2023622,8810132,252—15,0001,161,040
Jacqueline E. SheaChief Executive Officer, President2023750,6150491,873—12,1412,438,908
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024134
2023122
2022184
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue217,756832,01010,262,268
Cost Of Revenue———
Gross Profit———
Research And Development Expenses75,620,34086,676,563187,650,503
General And Administrative Expenses36,996,33847,582,10490,185,285
Operating Expenses112,616,678144,772,038277,835,788
Operating Income-112,398,922-143,940,028-267,573,520
Net Income-107,254,126-135,117,352-279,818,065
Earnings Per Share Basic-3.95-6.09-1.17
Earnings Per Share Diluted-3.95-6.09-1.17
Weighted Average Shares Outstanding Basic27,160,86322,173,662238,622,188
Weighted Average Shares Outstanding Diluted27,160,86322,173,662238,622,188
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents65,813,29714,310,86246,329,359
Marketable Securities Current28,300,232130,982,913206,669,397
Accounts Receivable1,199,05601,701,726
Inventories———
Non Trade Receivables———
Other Assets Current———
Total Assets Current97,830,050153,113,100315,242,680
Marketable Securities Non Current———
Property Plant And Equipment3,659,8184,960,9867,727,997
Other Assets Non Current1,979,654605,315684,044
Total Assets Non Current15,367,15617,838,32333,290,622
Total Assets113,197,206170,951,423348,533,302
Accounts Payable16,200,01319,847,74479,686,885
Deferred Revenue——0
Short Term Debt——1,067,000
Other Liabilities Current———
Total Liabilities Current35,325,58442,570,22896,868,074
Long Term Debt—016,614,840
Other Liabilities Non Current——0
Total Liabilities Non Current9,367,82711,032,06629,302,472
Total Liabilities44,693,41153,602,294126,170,546
Common Stock36,09922,792253,090
Retained Earnings-1,730,219,262-1,622,965,136-1,487,847,784
Accumulated Other Comprehensive Income-675,667-662,601-698,741
Total Shareholders Equity68,503,795117,349,129222,362,756
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization1,752,1472,621,6493,656,713
Share Based Compensation Expense6,595,10811,072,48622,555,419
Other Non Cash Income Expense22,466-317,997-1,074,830
Change In Accounts Receivable-1,206,172-9,332,9883,706,172
Change In Inventories———
Change In Non Trade Receivables———
Change In Other Assets-38,900-78,729-741,750
Change In Accounts Payable-3,367,087-45,989,06132,606,581
Change In Other Liabilities—0-14,826
Cash From Operating Activities-104,076,553-124,365,551-216,215,421
Purchases Of Marketable Securities54,138,026203,475,052248,528,843
Sales Of Marketable Securities158,637,578284,932,562361,083,850
Acquisition Of Property Plant And Equipment487,832320,898969,153
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities104,071,03987,355,875109,585,856
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock36,033,4735,461,74582,955,311
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities51,475,5464,995,09981,840,702
Change In Cash51,502,435-32,018,497-24,814,419
Cash At End Of Period65,813,29714,310,86246,329,359
Income Taxes Paid———
Interest Paid533,4871,066,9751,066,975
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-3.95-6.09-1.17
Price To Earnings Ratio-0.4633-1.005-16.0006
Earnings Growth Rate-35.1396420.5128-19.3103
Price Earnings To Growth Ratio0.0132-0.00240.8286
Book Value Per Share2.52225.29230.9319
Price To Book Ratio0.72561.156420.0896
Ebitda-105,324,146-131,272,914-274,907,400
Enterprise Value—121,396,384.17244,438,526,875.8916
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio—00.0795
Capital Expenditures450,979-145,362-6,068,496
Free Cash Flow-104,527,532-124,220,189-210,146,925
Return On Equity-1.5657-1.1514-1.2584
One Year Beta1.6391.78062.116
Three Year Beta1.94821.73570.4379
Five Year Beta0.61720.62990.6123
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Sumner Michael JohnChief Medical Officer2025-06-302,916A17,850
Sumner Michael JohnChief Medical Officer2025-06-302,916D0
Weiner David B.Director2025-05-212,167A86,620
Weiner David B.Director2025-05-212,167D0
DANSEY ROGER DDirector2025-05-212,167A8,916
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
ATWOOD & PALMER INC2025-09-3043182.3889
Green Alpha Advisors, LLC2025-09-30112,52648,0882.34
MJT & Associates Financial Advisory Group, Inc.2025-09-307613252.3415
Farther Finance Advisors, LLC2025-09-3037162.3125
OSAIC HOLDINGS, INC.2025-06-303,3371,6492.0237
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Advisors' Inner Circle Fund III2025-07-31I SharesKCXIX164232.880.0001
DFA INVESTMENT DIMENSIONS GROUP INC2025-07-31U.S. VECTOR EQUITY PORTFOLIO - INSTITUTIONAL CLASSDFVEX8631,225.460.0
Dimensional ETF Trust2025-07-31Dimensional U.S. Targeted Value ETFDFAT1,6022,274.840.0
iSHARES TRUST2025-06-30iShares Russell 2000 ETFIWM81,442165,734.470.0003
iSHARES TRUST2025-06-30iShares Micro-Cap ETFIWC81,645166,147.580.0203
This is a preview of the latest data. Subscribe to access the full data.